New Data at ESMO 2019 for Merck KGaA, Darmstadt, Germany, Highlight Focused Clinical Development and Commitment to Patient Care

Not intended for UK-based media Key ESMO Abstracts # BAVENCIO® (avelumab): 1451; 3152; 4174; 4256; 4823; 5113, ERBITUX® (cetuximab): 1212, 2589, 4455, Tepotinib (MET kinase inhibitor): 3930;…… Read more “New Data at ESMO 2019 for Merck KGaA, Darmstadt, Germany, Highlight Focused Clinical Development and Commitment to Patient Care”